

## HEOR Oncology Publications

Reyes C, **Engel-Nitz N, DaCosta Byfield S**, et al. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkins lymphoma. *Oncologist*. 2019 Feb 26. [Epub ahead of print]

Reyes C, **Engel-Nitz N, DaCosta Byfield S**, et al. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer. *Oncologist*. 2019 Feb 22. [Epub ahead of print]

Schwartzberg LS, **Lal L**, Balu S, Campbell K, **Brekke L**, et al. Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. *Clinicoecon Outcomes Res*. 2018;10:493-500.

Schwartzberg LS, **Lal L**, Balu S, Campbell K, **Brekke L**, et al. Clinical outcomes of treatment with filgrastim vs a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. *J Manag Care Spec Pharm*. 2018 Oct;24(10):976-984.

**Burton TM**, Ye X, **Parker ED, Bancroft T**, Healey J. Burden of illness associated with tenosynovial giant cell tumors. *Clin Ther*. 2018;40(4):593-602.

**Burton T**, Lapuerta P. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. *Future Oncol*. 2018 Oct;14(23):2361-2370.

Villalobos VM, **Byfield SD**, Ghate SR, **Adejoro O**. A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US. *Clin Sarcoma Res*. 2017;7:18.

**Mao J, McPheeters JT**, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study. *Medicine (Baltimore)*. 2017;96(48):e8746.

Gildea TR, **DaCosta Byfield S**, Hogarth DK, Wilson DS, Quinn CC. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. *Clinicoecon Outcomes Res*. 2017;9:261-269.

**DaCosta Byfield S**, Buck PO, **Blauer-Peterson C**, et al. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. *J Oncol Pract*. 2016;12(2):159-167.

**DaCosta Byfield S**, Buck PO, **Blauer-Peterson C**, Poston SA. Treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: a real-world retrospective study. *J Oncol Pract*. 2016;12(2):159-167.

**Burton T, Byfield SD**, Smith GL, et al. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database. *Curr Med Res Opin*. 2016;32(8):1417-1423.

Whyte JL, **Engel-Nitz NM, Teitelbaum A, Gomez Rey G**, Kallich JD. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. *Med Care*. 2015 Jul;53(7):e49-57.

**Henk HJ**, Woloj M, Shapiro M, Whiteley J. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. *Clin Ther*. 2015;37(1):124-133.

**Henk HJ**, Li X, **Becker LK**, et al. Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design. *J Comp Eff Res*. 2015;4(1):37-50.

**Engel-Nitz NM**, Hao Y, **Becker LK, Gerdes R**. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer. *J Comp Eff Res*. 2015 Aug;4(4):303-14.

**Byfield SA, McPheeters JT, Burton TM, Nagar SP, Hackshaw MD.** Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. *J Manag Care Spec Pharm.* 2015;21(6):515-522.

**Engel-Nitz NM, Eckert B, Song R, et al.** Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes. *BMC Clin Pathol.* 2014;14:17.

Smith BD, Beach CL, Mahmoud D, Weber L, **Henk HJ.** Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. *Exp Hematol Oncol.* 2014;3(1):10.

**Parthan A, Santos E, Becker L, et al.** Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab. *J Manag Care Spec Pharm.* 2014;20(5):485-493.

**Johnson P, Bancroft T, Barron R, et al.** Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. *Value Health.* 2014;17(4):380-389.

**Engel-Nitz NM, Yu EB, Becker LK, Small A.** Service setting impact on costs for bevacizumab-treated oncology patients. *Am J Manag Care.* 2014 Nov 1;20(11):e515-22.

**DaCosta Byfield S, Small A, Becker L, Reyes C.** Differences in treatment patterns and health care costs among non-Hodgkin's lymphoma and chronic lymphocytic leukemia patients receiving rituximab in the hospital outpatient setting versus the office/clinic setting. *J Cancer Therapy.* 2014;5(5):208-216.

**Brenneman SK, Belland A, Hulbert E, Leite J, Hall J, Nerenberg M.** Can an integrated pathology process and decision support tool improve diagnosis and treatment of hematologic malignancies? *J Clin Oncol.* 2014;32(15):e17622.

**Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ.** Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. *Oncologist.* 2013;18(1):37-45.

Reyes C, **DaCosta Byfield S, Linke R, Satram-Hoang S, Teitelbaum AH.** The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. *Melanoma Res.* 2013;23(2):159-166.

Ray S, **Dacosta-Byfield S, Ganguli A, Bonthapally V, Teitelbaum A.** Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. *J Neurooncol.* 2013;114(1):117-125.

Naeim A, **Henk HJ, Becker L, et al.** Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). *BMC Cancer.* 2013;13:11.

**Henk HJ, Chen C, Benedict A, Sullivan J, Teitelbaum A.** Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population. *Clinicoecon Outcomes Res.* 2013;5:347-354.

**Henk HJ, Becker L, Tan H, et al.** Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. *J Med Econ.* 2013;16(1):160-168.

**Henk H, Ray S.** Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer. *Lung Cancer Manage.* 2013;2(3).

**Henk H, Kaye J, Rothman K, et al.** Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. *Community Oncol.* 2013;10(1):16-26.

**Dacosta Byfield S, Yu E, Morlock R, Evans D, Teitelbaum A.** Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents. *J Med Econ.* 2013;16(8):1071-1081.

**DaCosta Byfield S, Nash Smyth E, Mytelka D, Bowman L, Teitelbaum A.** Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. *J Med Econ.* 2013;16(12):1379-1386.

**Dacosta Byfield S**, Chen D, Yim YM, Reyes C. Age distribution of patients with advanced non-melanoma skin cancer in the United States. *Arch Dermatol Res*. 2013;305(9):845-850.

**Chastek B, Kulakodlu M**, Valluri S, Seal B. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization. *Postgrad Med*. 2013;125(2):73-82.

Tschida SJ, Aslam S, **Lal L**, et al. Retrospective evaluation of an oral oncology specialty pharmacy program. *Am J Pharm Benefits*. 2012;4(4):165-174.

Kruzikas D, Smith JS, **Harley C, Buzinec P**. Costs associated with management of cervical human papillomavirus-related conditions. *Cancer Epidemiol Biomarkers Prev*. 2012;21(9):1469-1478.

**Henk HJ, Teitelbaum A**, Perez JR, Kaura S. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. *Am J Hematol*. 2012;87(5):490-495.

**Henk HJ**, Kaura S, **Teitelbaum A**. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. *J Med Econ*. 2012;15(1):195-204.

**Henk HJ**, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. *J Med Econ*. 2012;15(1):175-184.

**Henk HJ**, Kaura S. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. *J Med Econ*. 2012;15(1):185-194.

**Henk H, Teitelbaum A**, Kaura S. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid. *Curr Med Res Opin*. 2012;28(7):1119-1127.

**Engel-Nitz NM**, Satram-Hoang S, **Cao F**, Reyes C. Lung cancer: copayments and behavior following erlotinib formulary tier change. *Am J Pharm Benefits*. 2012;4(Special Issue):SP6-SP16.

**Chastek B, Harley C**, Kallich J, **Newcomer L**, Paoli CJ, **Teitelbaum AH**. Health care costs for patients with cancer at the end of life. *J Oncol Pract*. 2012 Nov;8(6):75s-80s.

Whyte JL, **Engel-Nitz N, Teitelbaum A, Gomez Rey G**, Kallich J. A validation study of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data (podium). Paper presented at: ISPOR 16th Annual International Meeting; 2011 May 21-25; Baltimore, MD.

**Nelson MA, Shetty S, Kulakodlu M, Harley C**, Seal B. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. *J Med Econ*. 2011;14(2):179-186.

Levy DE, **Byfield SD**, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. *Genet Med*. 2011;13(4):349-355.

Lau EC, Mowat FS, Kelsh MA, **Legg JC, Engel-Nitz NM, Watson HN, Collins HL, Nordyke RJ, Whyte JL**. Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data. *Clin Epidemiol*. 2011;3:259-272.

Lash S, **Teitelbaum A, Henk H**, Reyes C, Benn L. Costs associated with second-line therapies for lung cancer. *Am J Pharm Benefits*. 2011;3(1):21-29.